Seminars in Oncology
Volume 29, Issue 4 , Pages 389-399 , August 2002

Adjuvant therapy for patients with high-risk malignant melanoma

References 

  1. Kirkwood J, Strawderman MH, Ernstoff MS, et al.  Interferon alfa-2a adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol. 1996;14:7–17
  2. Kirkwood JM, Ibrahim JG, Sondak VK, et al.  High- and low-dose interferon alpha-2b in high-risk melanoma: First analysis of Intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444–2458
  3. Clark WH, Elder DE, Guerry DP, et al.  Model predicting survival in stage I melanoma based on tumor proression. J Natl Cancer Inst. 1989;81:1893–1904
  4. Soong S-J1, Weiss HL. Predicting outcome in patients with localized melanoma. In: ed 3.  Balch CM,  Houghton AN,  Sober AJ, et al. editor. Cutaneous Melanoma. St Louis, MO: Quality Medical Publishing; 1998;p. 51–61
  5. Tompsett KS, Elenitas R, Lessin S, et al.  Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Proc Am Soc Clin Oncol. 2000;19:565a; (abstr)
  6. Gershenwald JE, Colome MI, Lee JE, et al.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253–2260
  7. Gershenwald JE, Thompson W, Mansfield PF, et al.  Mult-institutional melanoma lymphatic mapping experience: The prognostic valus of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–983
  8. Gershenwald JE, Schacherer C, Emerson M, et al.  Patterns of failure and survival in sentinel lymph node positive melanoma patients. Proc Am Soc Clin Oncol. 2001;20:350a; (abstr)
  9. Essner R, Rose DM, Kojima M, et al.  Predicting the natural history of melanoma after tumor-negative sentinel lymph node dissection. Proc Am Soc Clin Oncol. 2001;20:350a; (abstr)
  10. Leong SP, Achtem TA, Miller JR, et al.  Clinical significance of melanoma micrometastasis to sentinel lymph nodes and other high risk factors. Proc Am Soc Clin Oncol. 2000;19:551a; (abstr)
  11. Nguyen CL, Mc Clay EF, Cole DJ, et al.  Melanoma thickness and histology predict sentinel lymph nodes status. Am J Surg. 2001;181:8–11
  12. Karjalainen JM, Kelloloski JK, Eskelinen MJ, et al.  Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol. 1998;16:3584–3591
  13. Buzaid AC, Ross MI, Soong S-J. Classification and staging. In: ed 3.  Balch CM,  Houghton AN,  Sober AJ, et al. editor. Cutaneous Melanoma. St Louis, MO: Quality Medical Publising; 1998;p. 37–49
  14. Gritters LS, Francis IR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluro-2-deoxy-d-glucose in the imaging of malignant melanoma. J Nucl Med. 1993;34:1420–1427
  15. Damian DL, Fulham MJ, Thompson E, et al.  Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 1996;6:325–329
  16. Rinne D, Baum RP, Hor G, et al.  Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography; results of a prospective study of 100 patients. Cancer. 1999;85:1199–1201
  17. Macfarlane DG, Sondak V, Johnson T, et al.  Prospective evaluation of 2-[18F]-2-deoxy-d-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol. 1998;16:1770–1776
  18. Wagner JD, Schauwecker D, Davidson D, et al.  Prospective study fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol. 1998;17:1508–1515
  19. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol. 1984;2:336–352
  20. Kirkwood JM, Ernstoff MS. Interferons—Clinical applications: Cutaneous melanoma. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Biologic Therapy of Cancer. Philadelphia, PA: Lippincott; 1991;p. 311–333
  21. Cascinelli N, Bufalino R, Morabito A, et al.  Results of adjuvant interferon study in WHO melanoma programme. Lancet. 1994;343:913–914
  22. Cascinelli N. Evaluation of efficacy of adjuvant rIFN-2A in melanoma patients with regional node metastases. Proc Am Soc Clin Oncol. 1995;14:410; (abstr)
  23. Hancock BW, Wheatley K, Harrison G, et al.  Aim high-adjuvant interferon in melanoma (high risk), a United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) randomized study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma. Proc Am Soc Clin Oncol. 2001;20:1394; (abstr)
  24. Cascinelli N, Belli F, MacKie RM, et al.  Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases form cutaneous melanoma: A randomised trial. Lancet. 2001;358:866–869
  25. Kirkwood JM, Ibrahim JG, Sosman JA, et al.  High-dose interferon alpha-2b significantly prolongs relapse-free and overall survival compared with GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: results of Intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370–2380
  26. Livingston PO, Wong GYC, Adluri S, et al.  Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994;12:1036–1044
  27. Hellinng F, Zhang S, Shang A, et al.  GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995;55:2783–2788
  28. Chapman PB, Morrissey DM, Panageas KS, et al.  Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: A dose-response study. Clin Cancer Res. 2000;6:874–879
  29. Pehamberger H, Soyer P, Steiner A, et al.  Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol. 1998;16:1425–1429
  30. Dranoff G, Jaffee E, Lazenby A, et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539–3543
  31. Spitler LE, Grossbard ML, Ernstoff MS, et al.  Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2000;18:1614–1621
  32. Spitler LE, Sagebiel R. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. N Engl J Med. 1980;303:1143–1151
  33. Lejeune FJ, Macher E, Kleeberg U. An assesement of DTIC versus levamisole or placebo in the treatment of high risk stage I patients under surgical removal of a primary melanoma of the skin. A phase II adjuvant study (EORTC protocol 18761). Eur J Cancer Clin Oncol. 1988;24(suppl 2):581–590
  34. Quirt IC, Shelley WE, Pater JL, et al.  Improved survival in patients with poor-prognosis malignant melanoma treated wtih adjuvant levamisole: A phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1991;9:729–735
  35. Spitler LE. A randomized trial of levamisole versus placebe as adjuvant therapy in malignant melanoma. J Clin Oncol. 1991;9:736–740
  36. DelPrete SA, Maurer LH, O'Donnell J, et al.  Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep. 1993;68:1403–1405
  37. McClay EF, Mastrangelo MJ, Bellet RE, et al.  Combination chemo/hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep. 1987;71:465–469
  38. McClay EF, Mastrangelo MJ, Berd D, et al.  Effective combination chemo/Hormonal therapy for malignant melanoma: Experience with three consecutive trials. Int J Cancer. 1992;50:553–556
  39. McClay EF, Sprandio JD, Mastrangelo MJ, et al.  Importance of tamoxifen to a combination chemotherapy regimen for melanoma. Proc Am Soc Clin Oncol. 1988;7:250; (abstr)
  40. McClay EF, McClay ME, Albright KA, et al.  Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma: A biologically important observation. Cancer. 1993;72:1914–1918
  41. Lattanzi SC, Tosteson T, Chertoff J, et al.  Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res. 1995;5:365–369
  42. Richards JM, Gilewski TA, Ramming K, et al.  Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer. 1992;69:427–429
  43. Saba HI, Cruse CW, Wells KE, et al.  Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: A University of South Florida and H. Lee Moffitt Melanoma Center study. Ann Plast Surg. 1992;28:65–69
  44. Creagan ET, Suman VJ, Dalton RJ, et al.  Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999;17:1884–1890
  45. Crowell EBJ, Higa GM. The chemohormonal therapy of metastatic melanoma: Possible benefit from tamoxifen. West Virginia Med J. 1993;89:233–235
  46. Mastrangelo MJ, Bellet RE, Berd D. Aggressive chemotherapy for melanoma. In:  DeVita VT,  Hellman SA,  Rosenberg SA editor. Principles and Practice of Oncology; PPO Updates. vol 5:Philadelphia, PA: Lippincot; 1991;p. 1–11
  47. Fierro MT, Bertero M, Novelli M, et al.  Therapy for metastatic melanoma: Effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Melanoma Res. 1993;3:127–130
  48. Rusthoven JJ, Quirt IC, Iscoe NA, et al.  Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol. 1996;14:2083–2090
  49. Johnston SRD, Constella DO, Moore J, et al.  Randomized phase II trial of BCDT (BCNU, cisplatin, dacarbazine and tamoxifen) with or without interferon alpha (IFN-alpha) and interleukin-2 (IL-2) in patients with metastatic melanoma. Proc Am Soc Clin Oncol. 1997;16:490; (abstr)
  50. Mitchell MS, VonEschen KB. Phase III trial of Melacine melanoma theracine versus combination chemotherapy in the treatment of stage IV melanoma. Proc Am Soc Clin Oncol. 1997;16:494; (abstr)
  51. Margolin K, Liu P-Y, Flaherty L, et al.  Phase II study of carmustine, dacarbazine, cisplatin and tamoxifen in advanced melanoma: A Southwest Oncology Group study. J Clin Oncol. 1998;16:664–669
  52. Chapman PB, Einhorn LH, Myers ML, et al.  Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastic melanoma. J Clin Oncol. 1999;17:2745–2751
  53. McClay EF, Christen R, Albright KA, et al.  Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res. 1992;52:6790–6796
  54. McClay EF, Albright KA, Jones JA, et al.  Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res. 1993;53:1571–1576
  55. McClay EF, Albright KA, Jones JA, et al.  Tamoxifen delays the in vitro development of resistance to cisplatin in human malignancies. Br J Cancer. 1994;70:449–452
  56. Mc Clay EF, Albright KD, Jones JA, et al.  Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int J Cancer. 1993;55:1018–1022
  57. McClay EF, McClay MET, Monroe L, et al.  The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high-risk melanoma. Br J Cancer. 2000;83:16–21
  58. Retsas S, Quigley M, Pectasides D, et al: Clinical and histologic involvement of regional lymph nodes in malignant melanoma.

☆ Address reprint requests to Edward F. McClay, MD, Melanoma Research Center of San Diego, 910 Sycamore Aue, Suite 102, Vista, CA 92083.

PII: S0093-7754(02)50269-4

doi: 10.1053/sonc.2002.34118

Seminars in Oncology
Volume 29, Issue 4 , Pages 389-399 , August 2002

Article Tools

* Image Usage & Resolution